• Mashup Score: 6
    Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults - 2 year(s) ago

    Heart failure (HF) affects 6.2 million adults in the United States, and prevalence is expected to increase.1 Black adults are more likely to develop HF compared with other racial groups.2 Incident HF rates have increased more in Black vs White adults, mostly owing to the increase in HF with preserved ejection fraction (HFpEF), which is associated with high morbidity and mortality and has few…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of robmentz
      robmentz

      Helpful data on biomarker changes & HF Risk "Longitudinal Changes in Troponin & Risk of HF Among Black Adults" 💠⬆️hs-cTnI on follow-up a/w ⬆️ HF risk 💠 Similar patterns for rEF & pEF @kershawpatel @ChrisDefilippi @ambarish4786 @JavedButler1 @HFSA https://t.co/1VFpXXY5No https://t.co/0tnOVEom82

  • Mashup Score: 14
    Mortality and Heart Failure Hospitalization Among Young Adults With and Without Cardiogenic Shock After Acute Myocardial Infarction - 2 year(s) ago

    Cardiogenic shock following acute myocardial infarction (AMI-CS) is a feared complication of acute coronary syndromes and is seen in approximately 5%–10% of patients following AMI1–4; it is the leading cause of AMI-related in-hospital mortality.5 Despite advancements in AMI care, AMI-CS continues to be prevalent and accounts for one-third of all cardiogenic shock (CS); associated mortality rates…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of robmentz
      robmentz

      🚨New insights on cardiogenic shock complicating AMI in young patients @JCardFail https://t.co/ptfXPvCZQv 🌟Accompanied by an impactful patient perspective from Rhonda Monroe https://t.co/kHS2Z2rGWg @ersied727 @JJheart_doc @DLBHATTMD @EBohula @RonBlankstein @dranulala @HFSA https://t.co/tvLJ72p1dS

    • Profile photo of JCardFail
      JCardFail

      RT @robmentz: 🚨New insights on cardiogenic shock complicating AMI in young patients @JCardFail https://t.co/ptfXPvCZQv 🌟Accompanied by an…

  • Mashup Score: 0
    Following Our Hearts: Prioritizing Self-care and Wellness - 2 year(s) ago

    At the journal, we (Anu and Rob) meet virtually with the HFSA Director of Publishing, Meredith Hurt, every Friday at noon. After spending some time talking through logistics (“Are any papers held up in review? Did we receive that invited editorial?”), most of our time is spent brainstorming on our JCF strategy: ‘what’s our next innovation to improve the journal?’ and ‘how can we think…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dranulala
      dranulala

      A piece @robmentz & I wrote last year on the uncanny example the #cardiovascular system is for us- emphasizing the critical importance of preserving one’s self and not operating on an “empty tank” https://t.co/3mI0fQfhoJ

  • Mashup Score: 4
    JCF Heart Failure Year-In-Review 2022… The Best is Yet to Come! - 2 year(s) ago

    2022 was a year of groundbreaking scientific advances for the heart failure (HF) community at large. Several landmark trials were presented and/or published that will have a significant impact on clinical practice. As we reflect on this productive year, we wanted to take the opportunity to summarize key results for some of these practice-changing trials, while highlighting important initiatives…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dranulala
      dranulala

      What year 2022 was in #FunctionNotFailure!! Check out our @JCardFail January Ed page led by @vbluml summarizing 🔑 trials in our field & specific JCF papers & initiatives!Looking forward to innovation & discovery in 2023! @robmentz https://t.co/VCySSnfQrF https://t.co/Zc0mnbrPNT https://t.co/Qasj95ipAq

  • Mashup Score: 19
    JCF Heart Failure Year-In-Review 2022… The Best is Yet to Come! - 2 year(s) ago

    2022 was a year of groundbreaking scientific advances for the heart failure (HF) community at large. Several landmark trials were presented and/or published that will have a significant impact on clinical practice. As we reflect on this productive year, we wanted to take the opportunity to summarize key results for some of these practice-changing trials, while highlighting important initiatives…

    Source: Journal of Cardiac Failure
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCardFail
      JCardFail

      Check out the JCF Heart Failure Year-In-Review 2022 Summary of Practice-Changing Trials of 2022 & Key Highlights from @JCardFail - Succinct Overview of High-Quality Science to Impact Patient Care @robmentz @vbluml @dranulala @HFSA https://t.co/F4mKshMZmw https://t.co/7NjNLUsjX4

  • Mashup Score: 0
    Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry - 2 year(s) ago

    Current practice guidelines recommend that patients with heart failure (HF) with reduced ejection fraction (HFrEF) be treated with multiple medications at target dosages derived from landmark randomized clinical trials, as tolerated.1–3 However, the use and dosing of these medications in routine practice typically falls short of levels achieved in clinical trials.4,5 As a way of improving…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SJGreene_md
      SJGreene_md

      @yaleHFdoc @JavedButler1 @gcfmd VICTORIA registry link below outlines use and dosing (but although SGLT2i included, this was prior to SGLT2i approval for HF) Also, multiple nice publications from #GWTGHF as well (pre- SGLT2i) https://t.co/E3tLMd1gpl

  • Mashup Score: 8
    Omecamtiv mecarbil: Decisional Dilemmas & Regulatory Science – Opportunities for Improvement? - 2 year(s) ago

    The Food and Drug Administration (FDA) is required to make decisions that can at times be controversial, for a myriad of reasons, on the benefits versus risks for medical products. This is understandable as science accelerates but with a suboptimal or more complex evidence generation system. For guidance on some of these decisions, the FDA occasionally asks an advisory committee to weigh in on…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dranulala
      dranulala

      Unique 💡insight from @texhern @DCRINews as to @US_FDA advisory board decision on #OmecamtivMecarbil & opportunities that lie ahead👇🏽 As always @JCardFail strives to be your home for all things #FunctionNotFailure promoting constructive discourse 🗣️ https://t.co/iiJTs1RfR7 https://t.co/wadMmi3IHW https://t.co/tgnq52WhvQ

  • Mashup Score: 0
    Blood coagulation disorders in heart failure: from basic science to clinical perspectives - 2 year(s) ago

    Heart failure (HF) is a clinical syndrome caused by a structural or functional disorder of the heart which results in elevated intracardiac pressures and/or inadequate cardiac output during exercise or rest [1] [REF], with the worldwide prevalence of 1-2% [2]. HF is divided into three subtypes, based on the left ventricular ejection fraction (LVEF): (i) HF with reduced ejection fraction (HFrEF),…

    Source: Journal of Cardiac Failure
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HanCardiomd
      HanCardiomd

      Blood coagulation disorders in HF: from basic science to clinical perspectives Thrombotic complications in HF patients are an underappreciated problem This review provided top 10 pearls in coagulation disorders management in #HeartFailure @JCardFail https://t.co/vItHTaVCS0 https://t.co/xcGgfqtP3k

Load More